Financial Review: LENZ Therapeutics (LENZ) vs. Its Competitors

LENZ Therapeutics (NASDAQ:LENZ) is one of 282 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare LENZ Therapeutics to similar companies based on the strength of its risk, earnings, institutional ownership, valuation, dividends, analyst recommendations and profitability.

Valuation and Earnings

This table compares LENZ Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.12
LENZ Therapeutics Competitors	$562.17 million	-$34.62 million	6.70

LENZ Therapeutics’ competitors have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 50.0% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares LENZ Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,428.78%	-224.08%	-44.94%

Analyst Ratings

This is a breakdown of recent recommendations for LENZ Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1422	4535	11770	202	2.60

LENZ Therapeutics currently has a consensus price target of $31.33, indicating a potential upside of 79.15%. As a group, “Biological products, except diagnostic” companies have a potential upside of 127.64%. Given LENZ Therapeutics’ competitors higher probable upside, analysts plainly believe LENZ Therapeutics has less favorable growth aspects than its competitors.

Volatility and Risk

LENZ Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ competitors have a beta of 0.99, indicating that their average stock price is 1% less volatile than the S&P 500.

Summary

LENZ Therapeutics beats its competitors on 7 of the 13 factors compared.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.